Evan Y. Yu, MD, discusses how the goals of therapy for a patient with newly- diagnosed metastatic hormone-sensitive prostate ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell ...

09, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, announced data highlighting that DARZALEX ® (daratumumab) subcutaneous (SC)-based regimens improve overall and ...